arrow
R

Ricard Mesı́a

Catalan Institute of Oncology
H指数:44
被引数:2.0万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Health-related quality of life outcomes from KEYNOTE-412: chemoradiotherapy with or without pembrolizumab in participants with head and neck squamous cell carcinoma

健康相关生活质量结局:来自KEYNOTE-412的研究——头颈鳞状细胞癌患者接受含或不含有pembrolizumab的化疗与放疗联合治疗的结果

2025-10-060
OAAI
Efficacy of anti-PD1 therapy in PD1-high mRNA tumors across multiple cancer types: results from cohort 1 and cohort 2 of the phase II SOLTI-1904 ACROPOLI trial

PD1疗法在PD1高表达mRNA肿瘤中的疗效:SOLTI-1904 ACROPOLI II期试验中队列1和队列2的结果

2025-09-300
OAAI
Nutritional impact of eicosapentaenoic acid supplementation (EPA) in patients with locally advanced head and neck cancer: a double-blind placebo-controlled randomized trial

局部晚期头颈癌患者补充二十碳五烯酸(EPA)的营养影响:一项双盲安慰剂对照随机试验

2025-09-290
OAAI
A multicenter retrospective analysis of recurrent/metastatic nasopharyngeal cancer from non-endemic areas: results in the pre-immunotherapy era

非流行区复发性/转移性鼻咽癌的多中心回顾性分析:免疫治疗时代前的结果

2025-09-020
PRE
Clarifying the consensus on laryngeal preservation strategies – Authors' reply

阐明喉保留策略的共识——作者回复

2025-09-010
PRE
Immune-based transcriptomic signature predicts CDK4/6 inhibitor efficacy in HR+/HER2– breast cancer

免疫相关转录组特征可预测HR+/HER2–乳腺癌中CDK4/6抑制剂的疗效

2025-08-070
OA
Nutritional characterization of patients with oropharyngeal cancers: impact of human papillomavirus status
2024-12-300
PRE
Salvage chemotherapy after progression on immunotherapy in recurrent/metastatic squamous cell head and neck carcinoma

复发/转移性鳞状细胞癌免疫治疗进展后的挽救性化疗

2024-11-250
OAAI
Is precision medicine the solution to improve organ preservation in laryngeal/hypopharyngeal cancer? A position paper by the Preserve Research Group
2024-08-062
OAAI
IMvoke010: A phase III, double-blind randomized trial of atezolizumab (atezo) after definitive local therapy vs placebo in patients (pts) with high-risk locally advanced (LA) squamous cell carcinoma of the head and neck (SCCHN)
2024-04-053
PRE
MOLTHY project (TTCC-2020-02): A Spanish observational study for MOLecular characterization of THYroid carcinoma
2023-10-010
OA
SAMHD1 expression is a surrogate marker of immune infiltration and determines prognosis after neoadjuvant chemotherapy in early breast cancer
2023-09-042
OAAI
TTCC-2019-02: real-world evidence of first-line cetuximab plus paclitaxel in recurrent or metastatic squamous cell carcinoma of the head and neck
2023-08-017
OAAI
Randomized phase 3 noninferiority trial of radiotherapy and cisplatin vs radiotherapy and cetuximab after docetaxel-cisplatin-fluorouracil induction chemotherapy in patients with locally advanced unresectable head and neck cancer

局部晚期不可切除头颈癌患者多西他赛-顺铂-氟尿嘧啶诱导化疗后放疗和顺铂vs放疗和西妥昔单抗的随机3期非劣效性试验

2022-11-014
PRE
SOLTI-1904 ACROPOLI TRIAL: efficacy of spartalizumab monotherapy across tumor-types expressing high levels of PD1 mRNA
2022-10-064
PRE
Paclitaxel Plus Cetuximab as Induction Chemotherapy for Patients With Locoregionally Advanced Head and Neck Squamous Cell Carcinoma Unfit for Cisplatin-Based Chemotherapy

紫杉醇联合西妥昔单抗诱导化疗不适合顺铂化疗的局部晚期头颈部鳞状细胞癌患者

2022-07-222
OAAI